TCDD-Inducible Poly-ADP-Ribose Polymerase (TIPARP), A Novel Therapeutic Target Of Breast Cancer

References

• Fan L, Strasser-Weippl K, Li -J-J, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–e289. doi:10.1016/S1470-2045(13)70567-924872111
   PubMed Web of Science ®Google Scholar
• Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–713. doi:10.1038/nm.433328481359
   PubMed Web of Science ®Google Scholar
• Behan FM, Iorio F, Picco G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568(7753):511–516. doi:10.1038/s41586-019-1103-930971826
   PubMed Web of Science ®Google Scholar
• MacPherson L, Tamblyn L, Rajendra S, Bralha F, McPherson JP, Matthews J. 2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation. Nucleic Acids Res. 2013;41(3):1604–1621. doi:10.1093/nar/gks133723275542
   PubMed Web of Science ®Google Scholar
• Marshall NB, Kerkvliet NI. Dioxin and immune regulation: emerging role of aryl hydrocarbon receptor in the generation of regulatory T cells. Ann N Y Acad Sci. 2010;1183:25–37. doi:10.1111/j.1749-6632.2009.05125.x20146706
   PubMed Web of Science ®Google Scholar
• Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology. 2009;127(3):299–311. doi:10.1111/j.1365-2567.2009.03054.x19538249
   PubMed Web of Science ®Google Scholar
• Busbee PB, Rouse M, Nagarkatti M, Nagarkatti PS. Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. Nutr Rev. 2013;71(6):353–369. doi:10.1111/nure.1202423731446
   PubMed Web of Science ®Google Scholar
• Esser C. Biology and function of the aryl hydrocarbon receptor: report of an international and interdisciplinary conference. Arch Toxicol. 2012;86(8):1323–1329. doi:10.1007/s00204-012-0818-222371237
   PubMed Web of Science ®Google Scholar
• Talari NK, Panigrahi MK, Madigubba S, Phanithi PB. Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma. J Neurooncol. 2018;137(2):241–248. doi:10.1007/s11060-017-2730-329302888
   PubMed Web of Science ®Google Scholar
• Goode EL, Chenevix-Trench G, Song H, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010;42(10):874–879. doi:10.1038/ng.66820852632
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY). 2004;6(1):1–6. doi:10.1016/S1476-5586(04)80047-2
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.00228732212
   PubMed Web of Science ®Google Scholar
• Jezequel P, Campone M, Gouraud W, et al. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 2012;131(3):765–775. doi:10.1007/s10549-011-1457-721452023
   PubMed Web of Science ®Google Scholar
• Jezequel P, Frenel JS, Campion L, et al. bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database (Oxford). 2013;2013:bas060. doi:10.1093/database/bat08123325629
   PubMedGoogle Scholar
• Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725–731. doi:10.1007/s10549-009-0674-920020197
   PubMed Web of Science ®Google Scholar
• Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805–D811. doi:10.1093/nar/gku107525355519
   PubMed Web of Science ®Google Scholar
• Haeussler M, Zweig AS, Tyner C, et al. The UCSC genome browser database: 2019 update. Nucleic Acids Res. 2019;47(D1):D853–d858. doi:10.1093/nar/gky109530407534
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–D452. doi:10.1093/nar/gku100325352553
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.21119131956
   PubMed Web of Science ®Google Scholar
• Davis AP, Grondin CJ, Johnson RJ, et al. The comparative toxicogenomics database: update 2019. Nucleic Acids Res. 2019;47(D1):D948–d954. doi:10.1093/nar/gky86830247620
   PubMed Web of Science ®Google Scholar
• Bansal C, Pujani M, Sharma KL, Srivastava AN, Singh US. Grading systems in the cytological diagnosis of breast cancer: a review. J Cancer Res Ther. 2014;10(4):839–845. doi:10.4103/0973-1482.14097925579516
   PubMed Web of Science ®Google Scholar
• Lee AH, Ellis IO. The Nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res. 2008;14(2):113–115. doi:10.1007/s12253-008-9067-318543079
   PubMed Web of Science ®Google Scholar
• Kucab JE, Zou X, Morganella S, et al. A compendium of mutational signatures of environmental agents. Cell. 2019;177(4):821–836.e816. doi:10.1016/j.cell.2019.03.00130982602
   PubMed Web of Science ®Google Scholar
• Shi M, Cao M, Song J, et al. PinX1 inhibits the invasion and metastasis of human breast cancer via suppressing NF-kappaB/MMP-9 signaling pathway. Mol Cancer. 2015;14:66. doi:10.1186/s12943-014-0278-925888829
   PubMed Web of Science ®Google Scholar
• Beck C, Rodriguez-Vargas JM, Boehler C, et al. PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers. Cell Death Differ. 2019;26(9):1615–1630. doi:10.1038/s41418-018-0233-130442946
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Walsh S, McDermott EW, Crown J. Biomarkers in breast cancer: where are we and where are we going? Adv Clin Chem. 2015;71:1–23. doi:10.1016/bs.acc.2015.05.00126411409
   PubMed Web of Science ®Google Scholar
• Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806–1814. doi:10.1200/JCO.2012.46.893423589557
   PubMed Web of Science ®Google Scholar
• Bagaria SP, Ray PS, Sim MS, et al. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg. 2014;149(2):125–129. doi:10.1001/jamasurg.2013.318124306257
   PubMed Web of Science ®Google Scholar
• Cui X, Yi Q, Jing X, et al. Mining prognostic significance of MEG3 in human breast cancer using bioinformatics analysis. Cell Physiol Biochem. 2018;50(1):41–51. doi:10.1159/00049395630278461
   PubMedGoogle Scholar
• Agarwal S, Chadha D, Mehrotra R. Molecular modeling and spectroscopic studies of semustine binding with DNA and its comparison with lomustine-DNA adduct formation. J Biomol Struct Dyn. 2015;33(8):1653–1668. doi:10.1080/07391102.2014.96887425350567
   PubMed Web of Science ®Google Scholar
• Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013;39(5):444–456. doi:10.1016/j.ctrv.2012.06.00722841437
   PubMed Web of Science ®Google Scholar
• Chae YK, Arya A, Malecek MK, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767–40780. doi:10.18632/oncotarget.819427004404
   PubMed Web of Science ®Google Scholar
• Jara JA, Lopez-Munoz R. Metformin and cancer: between the bioenergetic disturbances and the antifolate activity. Pharmacol Res. 2015;101:102–108. doi:10.1016/j.phrs.2015.06.01426277279
   PubMed Web of Science ®Google Scholar